| Regulator Gives Insurers Good News A first look at how a key provision in the federal health overhaul could be implemented suggests that insurers' profits won't take the hit that the industry had feared. online.wsj.com |
Mass. Race Highlights Health Care Sensitivity over health-care costs in Massachusetts is at the forefront of a tight three-way race for governor, and may offer a glimpse of how the overhaul will play out in elections to come. online.wsj.com |
ImmunoCellular Therapeutics: A Decent Long-Term Pick VFC submits: It's been a roller-coaster ride over the past few months for shares of ImmunoCellular Therapeutics (IMUC.OB), a ride that saw the stock trade as high as $2.44 before retreating back down to the one dollar range.The pipeline of this company is still in the earlier stages of development, with nothing yet in Phase II, although a Phase II trial for ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma, is planned for the second half of 2010.Complete Story » seekingalpha.com |
Researchers Beaming at Light's Medical Uses Researchers at the Massachusetts Institute of Technology are studying how to replace diabetics' daily finger-prick blood tests with a beam of light. online.wsj.com |
Feds Intervene in Pfizer Suit Over Illegal Drug Promotion Pharmalot submits: Four months after two sales reps caused a sensation by charging that Wyeth (WYE) illegally promoted its Rapamune kidney transplant drug for use with other organs and targeted African-Americans, the federal government has filed a motion with a federal court to intervene, or join their whistleblower lawsuit. In a document (pdf) filed Tuesday in US District Court in Philadelphia, the US Attorney for Pennsylvania and 19 states, along with the District of Columbia, wrote that “the United States has established good cause to intervene…” An accompanying memorandum, however, was filed separately under seal. Wyeth, by the way, is now part of Pfizer (PFE).Complete Story » seekingalpha.com |